These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 18497976)

  • 1. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
    Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
    Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; Nijman HW
    Cochrane Database Syst Rev; 2014 Sep; (9):CD007287. PubMed ID: 25229990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
    Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
    Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
    MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic and immunologic therapies for ovarian cancer.
    Berek JS; Schultes BC; Nicodemus CF
    J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy in epithelial ovarian carcinoma: hope and reality].
    Lavoué V; Foucher F; Henno S; Bauville E; Catros V; Cabillic F; Levêque J
    J Gynecol Obstet Biol Reprod (Paris); 2014 Mar; 43(3):198-210. PubMed ID: 24230482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific immunotherapy in ovarian cancer: a systematic review.
    Aalipour S; Zoghi S; Khalili N; Hirbod-Mobarakeh A; Emens LA; Rezaei N
    Immunotherapy; 2016 Oct; 8(10):1193-204. PubMed ID: 27605068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunotherapy of patients with ovarian cancer.
    Hwu P; Freedman RS
    J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in ovarian cancer.
    Krishnan V; Berek JS; Dorigo O
    Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy opportunities in ovarian cancer.
    Chu CS; Kim SH; June CH; Coukos G
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
    Berek JS
    Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of monoclonal antibodies in the treatment of ovarian cancer.
    Mabuchi S; Morishige K; Kimura T
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):3-8. PubMed ID: 19770762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
    Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
    Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current approaches in ovarian cancer vaccines.
    Reinartz S; Wagner U
    Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.
    Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J
    J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
    Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ
    Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies therapies for ovarian cancer.
    Leone Roberti Maggiore U; Bellati F; Ruscito I; Gasparri ML; Alessandri F; Venturini PL; Ferrero S
    Expert Opin Biol Ther; 2013 May; 13(5):739-64. PubMed ID: 23373587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.